Tanabe Mitsubishi Holds Seminar on Withdrawing Remicade Treatment After Remission
This article was originally published in PharmAsia News
Tanabe Mitsubishi held a seminar entitled, “Future Forecast of Rheumatoid Arthritis Treatment” 10 years after it received approval for Japan’s first biological agent, Remicade (infliximab).
You may also be interested in...
Designed to decrease venous leak from the corpora cavernosa, Giddy makes its Eddie device in oblong shape that opens at one point into two S-forms. Elastic bands are placed around the S-forms to pull the shape together at variable tensions.
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.